Gene Combination Transfer to Block Autoimmune Damage in Transplanted Islets of Langerhans by Bertera, Suzanne et al.
Experimental Diab. Res., 5:201–210, 2004
Copyright c  Taylor and Francis Inc.
ISSN: 1543-8600 print / 1543-8619 online
DOI: 10.1080/15438600490486822
Gene Combination Transfer to Block Autoimmune Damage
in Transplanted Islets of Langerhans
Suzanne Bertera,1 Angela M. Alexander,1 Megan L. Crawford,1 Glenn Papworth,2
Simon C. Watkins,2 Paul D. Robbins,3 and Massimo Trucco1
1Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine,
Rangos Research Center, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
2Department of Cell Biology and Physiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
3Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine,
Pittsburgh, Pennsylvania, USA
Islet transplantation therapy would be applicable to a
wider range of diabetic patients if donor islet acceptance
and protection were possible without systemic immuno-
suppression of the recipient. To this aim, gene transfer
to isolated donor islets ex vivo is one method that has
shown promise. This study examines the combined effect of
selected immunomodulatory and anti-inﬂammatory genes
known to extend the functional viability of pancreatic islet
grafts in an autoimmune system. These genes, indoleamine
2,3-dioxygenase (IDO), manganese superoxide dismutase
(MnSOD), and interleukin (IL)-1 receptor antagonist pro-
tein (IRAP), were transferred to isolated NOD donor islets
ex vivo then transplanted to NODscid recipients and evalu-
ated in vivo after diabetogenic T-cell challenge. The length
of time the recipient remained euglycemic was used to mea-
sure the ability of the transgenes to protect the graft from
autoimmune destruction. Although the results of these co-
transfections gave little evidence of a synergistic relation-
ship, they were useful to show that gene combinations can
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be used to more efﬁciently protect islet grafts from diabeto-
genic T cells.
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Type 1 diabetes is a disease that results from the T-cell–
mediated progressive and selective destruction of pancreatic
betacells.Thesecells,locatedintheisletsofLangerhans,phys-
iologically produce insulin as a regulatory response to glucose
levelsintheblood.Transplantationofdonorisletsisgainingfa-
vorasanalternativetherapytomultiple,dailyinsulininjections
fortreatmentofthisdisease.Therecentsuccessofanislettrans-
plantation regimen developed in Edmonton, Alberta, Canada,
has led to long-term euglycemia for some diabetic patients [1].
However,thepricepaidforthiscureisthelife-longadministra-
tion of systemic immunosuppressive drugs. Even though these
drugs are nonsteroidal and therefore less toxic for the beta cells
themselves, this long-term therapy is only recommended for
patients who have “brittle” diabetes and are prone to failure in
managing hyperglycemia sufﬁciently well with exogenous in-
sulin. Therefore, this therapy is not recommended for young,
type 1 diabetic patients who are able to manage their disease
with daily injections of insulin. In these cases, the risks of life-
long insulin therapy are preferred to the risks of drug toxicity
from a life-long immunosuppressive regimen [2].
Oneofthewaysbeingexploredtoimproveisletreplacement
therapy is to manipulate donor islets before transplantation by
201202 S. BERTERA ET AL.
ex vivo gene transfer to protect the graft from destruction and
circumventtheneedforsystemicimmunosuppressionofthere-
cipient.Oncethismethodofisletprotectionissuccessful,trans-
plantation may beneﬁt a wider range of diabetic patients. How-
ever,becausetheetiopathogenesisofdiabetesisquitecomplex,
it is unlikely that just one gene will be found that could block
autoimmune insulitis, prevent islet cell dysfunction and apop-
tosis, protect beta cells from reactive oxygen species (ROS),
and inhibit the immune rejection of islet allografts. In previous
studies, we have tested some promising immunoregulatory and
antioxidant genes in vitro [3–5] and in vivo, individually [3, 4].
Gene transfer was accomplished using replication-deﬁcient,
E1- and E3-deleted, ﬁrst-generation adenoviral vectors to ferry
the transgene into the target cells. The adeno-constructs were
able to infect the outermost cells comprising each islet. The
resulting expression of the cytomegalovirus (CMV) promotor–
driventransgeneintheseoutercelllayersprovidedenoughpro-
tection from the immediate environment to extend (compared
to controls) the functional life of the transplanted islets after
exposure to activated diabetogenic T-cells. With the promis-
ing results of these single-gene transfers, we went further by
selectively combining these genes to test whether a synergistic
effectmayevenfurtherprolongisletfunctionafterdiabetogenic
T-cell exposure. The genes we have included are indoleamine
2,3-dioxygenase (IDO), interleukin (IL)-1 receptor antagonist
protein (IRAP or IL-1Ra), and manganese superoxide dismu-
tase (MnSOD).
IDO is an enzyme involved in the catabolism of tryptophan
and has been shown to play a role in the immune response by
limiting T-cell proliferation [6, 7]. IRAP is a naturally occur-
ring, nonsignaling competitor for the IL-1 receptor [8]. IRAP
bindingisthoughttoblockinsulitisandautoreactivitybyblock-
ing IL-1β–induced expression of inducible nitric oxide syn-
thase (iNOS) [9] and the Fas receptor [10]. An antioxidant
enzyme was included because pancreatic islets have been ob-
served to be sensitive to oxidative damage [11]. MnSOD in
particular was chosen because it is expressed in response to in-
ﬂammatory cytokines [12, 13] but is not found in abundance in
pancreatic islets [14]. Three combinations of these genes, IDO
plus MnSOD, MnSOD plus IRAP, and IDO plus IRAP, were
transferred to isolated islets ex vivo by adenoviral infection.
MATERIALS AND METHODS
Experimental Animals
NOD/LtSzJ (NOD) female mice, 3 to 4 weeks of age (non-
diabetic islet donors) or 12 to 20 weeks of age (diabetic spleen
cell donors), and NOD.CB17-Prkdcscid/J (NODscid) female
mice, 8 to 12 weeks of age (islet recipients), were obtained
from Jackson Laboratories (Bar Harbor, ME). All mice were
keptinanAmericanAssociationofLaboratoryAnimalScience
(AALAS)-certiﬁedanimalfacilityintheRangosResearchCen-
terattheChildren’sHospitalofPittsburgh(CHP)andhousedin
microisolatorcagingwithinNationalInstitutesofHealthguide-
linesforanimalcareinaspeciﬁcpathogen–free(SPF)environ-
ment.Theresearchprotocolsforthisexperimentwereapproved
by the CHP Animal Research and Care Committee.
Islet Isolation and Culture
Mouse islets were isolated from the exocrine pancreas by
collagenase digestion under sterile conditions, following the
previously published classical method [15]. After separation
on a Ficoll gradient, the islets were further puriﬁed by hand
picking to eliminate any remaining exocrine tissue. Whole
islets were maintained in culture medium consisting of RPMI
1640 medium supplemented with 10% fetal calf serum (FCS),
20 mM HEPES, 1% L-glutamine, 1% penicillin/streptomycin,
and 50 µM β-mercaptoethanol (2-ME) at 37◦Ci na natmo-
sphere of 95% air, 5% CO2.T issue culture reagents were pur-
chased from Life Technologies (Grand Island, NY). Collage-
nase type V, Ficoll type 400, and 2-ME were purchased from
Sigma (St. Louis, MO).
Adenoviral Vectors
Replication-deﬁcient, E1- and E3-deleted, ﬁrst-generation
recombinant adenoviral vectors were utilized in these experi-
ments.AlltransgenicvectorscontainedtheCMVpromotor.The
murineIDOvectorwasclonedintoapBluescriptvectorandin-
serted into the pQBI-AdCMV5-BFP transfer vector to produce
Ad-IDO [3]. Human MnSOD was cloned into pAD·CMV link
theninsertedintotheAd5.sub360transfervectortoproduceAd-
MnSOD [4]. The human IRAP vector (Ad-IRAP), provided by
Amgen (Boulder, CO), and the beta-galactosidase vector (Ad-
LacZ), provided by Genvec (Rockville, MD), were propagated
and provided by the University of Pittsburgh Vector Core [16].
Gene Transfer to Islets
Islets were incubated singly or with combinations of Ad-
IDO-BFP, Ad-IRAP, Ad-MnSOD, and Ad-LacZ vectors in
serum-free medium at a multiplicity of infection (MOI) of 100
for each gene for approximately 1 hour at room temperature
with agitation every 15 minutes. An MOI of 100 was chosen
based on dose-response experiments showing an infection rate
of 70% to 90% of the surface area of the islets without cyto-
toxic effects [3, 4, 17]. After infection, islets were placed back
in complete media and incubated for 2 to 4 days before further
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Cell Preparation and FACS Analysis
Twot o4days after infection with a combination of Ad-
IDO-BFP and Ad-MnSOD transgenes, islets were dissociated
to single cells with enzyme-free dissociation buffer (Gibco-
BRL),washed,andplacedinﬂuorescence-activatedcellsorting
(FACS) medium (Hank’s buffered saline solution [HBSS] with
0.1% sodium azide and 0.5% bovine serum albumin [BSA]).
The single cells were incubated with an MnSOD antibody for
20 minutes, then washed and ﬁxed with 2% paraformaldehyde
(PFA). Flow cytometry was done on a FACSCalibur ﬂow cy-
tometer (Becton Dickinson). Analysis was performed 3 times
on groups of 200 islets isolated and infected on 3 separate
occasions.
Antibody Staining of MnSOD
Whole islets infected with Ad-IDO-BFP and Ad-MnSOD
were ﬁxed in a 2% PFA and permeabilized with 0.1% Triton-X
solution. After blocking with goat serum, the primary rabbit
polyclonal immunoglobulin G (IgG) MnSOD antibody (Up-
stateBiotechnology,LakePlacid,NY)wasaddedfor2hours.A
ﬂuorophore-labeled secondary antibody, Alexa Fluor 488 goat
anti-rabbitIgG(MolecularProbes,Eugene,OR),wasaddedfor
a1hour incubation protected from light.
Detection of Secreted IRAP Protein
Secreted protein was detected with an enzyme-linked im-
munosorbent assay (ELISA) kit (R&D Systems, Minneapolis,
MN). Isolated islets transfected with Ad-IRAP before trans-
plantation and Ad-IRAP islet grafts that survived T-cell chal-
lenge for 90 days were cultured for 48 hours. The supernatant
was then collected and assayed in triplicate for IRAP concen-
tration by ELISA.
Multiphoton Microscopy
Islets were imaged using a multiphoton laser scanning con-
focal microscope comprised of a titanium-sapphire ultrafast
tunable laser system (Coherent Mira Model 900-F, Olympus
Fluoview confocal scanning electronics), an Olympus IX70 in-
verted microscope with custom built power attenuation, and
external PMT detection systems. The three-dimensional multi-
photon data stack acquisition utilized 2 photon excitation at
800 nm (BFP) and 870 nm (Alexa Fluor 488, Cy 3), with
ﬂuorescence emission detected using D450/50M, HG510/50,
and HQ580/60 steep bandpass emission ﬁlters (Chroma,
Brattleboro, VT).
Streptozotocin Treatment
NODscid recipients were rendered diabetic with a single
high dose (230 mg/kg) of streptozotocin (STZ) dissolved in a
0.9% physiological saline solution and immediately injected
intraperitoneally [18]. The animals were monitored by blood
glucose readings from the tail vein until hyperglycemia was
established. An animal was considered diabetic after 2 consec-
utive readings of 300 mg/dL or higher.
Islet Transplantation and Graft Recovery
A total of 300 to 400 islets were transplanted per mouse.
Under sterile conditions, the recipient animal was anesthetized
with a 2.5% solution of avertin, injected intraperitoneally at
a dose of 0.015 to 0.017 mL/g body weight [19]. The kidney
wasexternalizedthroughasmallincisionintheﬂank.Theislets
wereaspiratedintoPE50tubing(HarvardApparatus,Holliston,
MA),centrifugedlightly,thendepositedintothespacebetween
the capsule and the kidney. The kidney was replaced in the ab-
dominal cavity and the incision closed with small wound clips.
Eitherunmodiﬁedortransgene-bearingisletsisolatedfrom3-to
4-week-oldNODmiceweretransplantedintoatotalof92STZ-
treated NODscid animals. Transplanted animals were moni-
tored for 1 to 2 weeks to establish the primary function of
the graft. Only animals exhibiting sustained euglycemia (70 to
150mg/dL)duringthistimewereincludedinthestudy.Forgraft
recovery,thekidneywasexposedasinthetransplantprocedure.
The renal artery and vein were ligated with 6–0 silk suture and
the kidney was separated from the body and retained for histo-
logic analysis. The wound was closed as before and the animal
allowed to recover. If hyperglycemia was evident in 2 to 5 days
after graft removal, the animal was considered graft dependant.
Autoimmune Challenge In Vivo
Spleens were removed from spontaneously diabetic NOD
female mice (blood glucose > 300 mg/dL). A single-cell sus-
pension was prepared by manual disruption of the spleen and
passagethrougha40-µmnylonmesh.NODscidrecipientstobe
challenged were injected intraperitoneally with approximately
20 × 106 spleen cells [20]. Blood glucose levels were moni-
tored for 90 days. Any animal remaining euglycemic after 90
days had the graft-bearing kidney removed to determine if eu-
glycemia was graft dependant.
Statistical Analysis
A 2-sample t test for independent samples with unequal
varianceswasusedtotestforstatisticalsigniﬁcanceofthemean
time of graft function for each experimental animal group in
comparisontothepooledcontrolgroup.Kaplan-Meieranalysis
was used to calculate the survival curves.204 S. BERTERA ET AL.
RESULTS
Islet Transgene Infection Patterns
In our previous studies, NOD islets were infected ex vivo
with 100 infectious particles per target cell (multiplicity of in-
fectionorMOI).Isletsinfectedinthiswayandtransplantedinto
a syngeneic host show transgene expression in excess of 100
days[3,4].Forthisstudy,wecoinfectedisletgroupswith2ade-
noviral vectors (100 MOI of each) for each gene combination.
This was done so as not to dilute the infection rate for either
transgene. Figure 1 is an example of islets genetically modiﬁed
with 2 transgenic adenoviral vectors. The blue color (DAPI ﬁl-
ter) is the result of cell infection with Ad-IDO-BFP, a vector
containing IDO plus a blue ﬂuorescent protein (BFP) in the
construct. Unfortunately, this BFP was found to fade quickly.
Therefore, this ﬁgure could not be used for a quantitative anal-
FIGURE 1
Distribution of transgene-bearing islet cells in whole murine
islets after co-infection with 2 adenoviral transgene
constructs. Islets were simultaneously incubated with 2
different constructs at 100 MOI each for 1 hour at RT with
agitation. The blue color indicates the Ad-IDO-BFP construct.
Green is produced by a FITC-labeled antibody bound to the
Ad-MnSOD in the infected cells. The red color is a nuclear
background stain. Yellow color is produced by the
superimposition of green and red ﬂuorophores. Original
magniﬁcation 40×.
ysis of infection. The green color (ﬂuorescene isothiocyanate
[FITC]ﬁlter)representscellsinfectedwithAd-MnSOD.Inthis
case, infected islets were stained with an MnSOD antibody
followed by Alexa Fluor 488 goat anti-rabbit IgG (Molecular
Probes, Eugene, OR), a ﬂuorophore-labeled secondary anti-
body. Rhodamine phalloidin (red color) was used to label cel-
lular F-actin as a counterstain. Most of the adeno-infected cells
are found in the external layers of the islet as was also shown in
previousstudies[4].Theyellowcolorisabackgroundeffectthat
resultsfromthesuperimpositionofgreenandredﬂuorophores.
Percentage of Islet Cells Infected by Each
Viral Vector
Aftersimultaneousadenoviralinfectionof2individualgene
constructs into whole isolated NOD islets, FACS analysis was
performed to identify the percentage of cells infected by each
gene. Islets infected with Ad-IDO-BFP and Ad-MnSOD were
disassociated into single cells 48 to 96 hours after infection
and sorted to identify the percentage of cells carrying each
marker gene. Figure 2A and B show representative dot plots
of the results of 2 color FACS analysis. Figure 2A shows non-
infected control islet cells gated so that the majority (>99%)
are in the lower left (LL), double-negative quadrant. Figure 2B
on the right shows the results of the combined gene constructs
96 hours after infection. Using the same gate as for controls,
double-negative cells are in the LL quadrant (∼70%), cells in-
fected with Ad-IDO-BFP only are represented in the upper left
(UL) quadrant (3.62%), Ad-MnSOD only are in the lower right
(LR)quadrant(5.82%),andthoseco-infectedwithbothvectors
are in the upper right (UR) quadrant (14.32%). Adding these 3
quadrant values together for total cells infected, 23.76% of the
islet cells were expressing either one or both transgenes in this
group, with the majority (14.32%) coinfected with both vec-
tors. The total number of cells expressing MnSOD is 20.14%
(LR + UR) and those expressing IDO total 17.94% (UL +
UR). The graph in Figure 2C shows the average percentage
of single-gene and double-gene–expressing islet cells from 4
independently infected groups of islets. The last column repre-
sentsanunrelatedgroupofisletswithasingle-genetransferred,
introduced here for comparison.
Duration of Graft Function With Single-Gene
Expression
Results from our 2 previous in vivo studies of Ad-IDO and
Ad-MnSOD as single-gene modiﬁcations are summarized in
Table 1 along with current results obtained from Ad-IRAP–
expressing islet grafts [3, 4]. All three of these single genetic
modiﬁcations resulted in signiﬁcant prolongation of islet func-
tion when compared to controls. The NODscid transplanted
control mice listed in Table 1 include grafts composed of eitherGENE COMBINATION TRANSFER TO ISLETS 205
FIGURE 2
Quantitative analysis of gene transfer to islet cells. Islets simultaneously infected with Ad-IDO-BFP plus Ad-MnSOD were
cultured for 4 days and dispersed to single cells for FACS analysis. (A) Representative dot plot of unmodiﬁed (control) islet cells.
(B) Representative dot plot of infected cells. Lower left (LL) quadrant represents double-negative cells, upper left (UL) quadrant
represents cells expressing IDO only, lower right (LR) represents cells expressing MnSOD only, and upper right (UR) represents
cells coinfected with both IDO and MnSOD. (C) Results of FACS analysis from 4 independent experiments calculated as mean
percentage ± SEM of islet cells transfected with adeno-gene constructs. The ﬁrst column on the left represents noninfected
control cells. The central columns divide the combination infections into 4 categories: the percentage of total cells bearing
Ad-IDO-BFP (second column), the total cells bearing Ad-MnSOD (third column), cells that coexpress Ad-IDO-BFP and
Ad-MnSOD (fourth column), and the total amount of infected cells in the islet population (ﬁfth column). The last column on the
right represents an unrelated single gene infection shown here for comparison.206 S. BERTERA ET AL.
TABLE 1
Duration of function of in vivo T cell–challenged islet grafts
n Mean ± SD Range P value
Single gene modiﬁcations∗
Ad-IDO 14 43 ± 15 24–83 <.005
Ad-MnSOD 12 47 ± 14 32–76 <.005
Ad-IRAP 11 46 ± 23 16–90 .005
Combinations∗
Ad-IDO 11 41 ± 22 19–77 .062
+ Ad-MnSOD
Ad-MnSOD 9 50 ± 18 30–90 <.005
+ Ad-IRAP
Ad-IDO 10 41 ± 20 19–90 .066
+ Ad-IRAP
Controls
Unmodiﬁed 11 31 ± 9 19–61
Ad-LacZ∗ 14 28 ± 14 7–61
Non-Tx 18 33 ± 7 23–49
Pooled∗∗ 43 32 ± 11 7–61
Note. Length of function of modiﬁed islet grafts was measured as
days of euglycemia after diabetogenic spleen cell challenge. For each
group, day 0 was considered the day of challenge; “n” is the number
of animals per group; mean ± SD is the mean number plus/minus
standard deviation of days of euglycemia after challenge. Range is the
shortest and longest duration of eulycemia of individuals within each
group. P value was calculated against the pooled controls.
∗Islets were incubated with a concentration of 100 MOI of each gene
per infection.
∗∗Unmodiﬁed, Ad-LacZ, and Non-Tx control groups were pooled
together for statistical calculations.
unmodiﬁed islets or Ad-LacZ–infected islets from young NOD
mice. A third group of nontransplanted NODscid mice was in-
cluded with every group of spleen cell challenges as a control
for the adoptive transfer of disease. A survival curve of the 3
control groups is shown in the bottom panel of Figure 3. For
purposes of calculating statistical signiﬁcance, these 3 control
groups were pooled together.
For the single-gene–bearing grafts, it was previously found
thatbothAd-IDOandAd-MnSODsigniﬁcantlyprolongedislet
graftfunction,withstrongstatisticalsigniﬁcanceformeandays
of function after challenge compared to the pooled control
group (P <. 005). In the new data obtained in this study,
Ad-IRAP was also found to signiﬁcantly lengthen graft func-
tion. The middle graph in Figure 3 tracks the length of func-
tion (in days) after T-cell challenge for each set of grafts, with
single-gene expression compared to the pooled controls. The
single-gene group containing Ad-IRAP had the only animal
that remained euglycemic for the full 90-day goal of the exper-
iment. The graft-bearing kidney was removed from the animal
and the graft was cultured in 2 mL medium and incubated at
TABLE 2
Secreted IRAP production (ng/mL)
Unmodiﬁed Ad-LacZ Ad-IRAP
Before transplantation Undetectable Undetectable 29 ± 3.3
After transplantation Undetectable Undetectable 8.2 ± 5.1
Note. Production of IRAP by murine islets after infection with Ad-
IRAP(100MOI)andAD-LacZ(100MOI)orunmodiﬁedislets.Before
transplantation: groups of 300 to 400 islets were isolated, exposed to
adenoviral vectors for 1 hour or not (unmodiﬁed group) and incubated
at 37◦C for 48 hours before the supernatant was tested by ELISA in
triplicate. After transplantation: If still functional 90 days after T-cell
challenge, the graft was removed and placed in culture for 48 hours.
These included one graft each of IRAP alone, MnSOD & IRAP, and
IDO & IRAP. The supernatant was assayed as before. For this experi-
ment, unmodiﬁed and Ad-LacZ grafts were not challenged.
37◦C for 48 hours. The supernatant showed that IRAP was still
detectable by ELISA whereas levels in control grafts were un-
detectable (Table 2).
Duration of Graft Function With Double-Gene
Expression
In order to test for possible synergistic effects of multiple
genes,isletsweresimultaneouslyinfectedwith2transgenecon-
structs. The results of the in vivo experiments are summarized
in Table 1. Although the IDO plus MnSOD–expressing islets
showed a strong trend toward increased survival, with a mean
time of graft function of 41 days, these results did not quite
reachstatisticalsigniﬁcancewhencomparedtothepooledcon-
trolgroup(P = .062).ThecasewassimilarforIRAPandIDO,
also with a mean of 41 days (P = .066). The combination of
IRAPandMnSODhowever,wassigniﬁcantlylongerat50days
thanthepooledcontrolsat32days(P ≤ .005).Asinthecaseof
the single-gene groups, only the double-gene groups contain-
ing IRAP had animals that remained euglycemic for 90 days
(one in each group). These grafts were removed and assayed
in triplicate for secreted IRAP by ELISA. A mean average of
the grafts plus the single-gene graft containing IRAP showed
that the grafts were secreting about a third of that before trans-
plant (Table 2). The top graph in Figure 3 tracks the length of
function(indays)afterchallengeforthe3setsofgraftsexpress-
ing transgene combinations compared to the pooled controls.
Figure 4 shows the individual glycemic proﬁles for the combi-
nation groups and randomly selected controls.
DISCUSSION
We have shown in islet cells that it is possible to simul-
taneously infect with 2 adenoviral vectors, each expressing a
differentgene,andthatthetotalpercentageofinfectedisletcells
is similar, on average, to islets infected with a single vector. WeGENE COMBINATION TRANSFER TO ISLETS 207
FIGURE 3
Survival data of islet grafts after challenge with spleen cells from spontaneously diabetic NOD mice. The top panel shows islet
grafts expressing gene combinations. IDO and IRAP ( ), IDO and MnSOD (  ), IRAP and MnSOD (×), and pooled controls ( ).
Middle panel shows single gene islet grafts with either IDO ( ), IRAP ( ), or MnSOD (  ) gene expression and pooled controls
( ). The bottom panel shows the control groups consisting of unmodiﬁed NOD islet grafts ( ), Ad-LacZ expressing NOD islet
grafts (  ), and nontransplanted (Non-Tx) NODscid mice ( ) included as controls for adoptive transfer of disease.208 S. BERTERA ET AL.
FIGURE 4
Individual glycemic proﬁles of combination islet grafts and controls. The day of T-cell challenge is indicated as day 0. Other
points indicated include day of transplantation (Tx) and day of graft-bearing kidney removal (Neph). Glycemic values of >300
mg/dL were considered as conﬁrmation of diabetes. Panels in order from top are IDO & IRAP, MnSOD & IRAP, IDO &
MnSOD, and controls at the bottom. The controls were split into 2 groups for clarity, transplanted controls on the lower left and
Non-Tx (nontransplanted controls) on the lower right. Of the 25 unmodiﬁed and Ad-LacZ control transplants actually performed,
half were selected at random for editorial purposes, and shown in this ﬁgure. Individuals of the other groups are shown in their
entirety. The nontransplanted animals were controls for the transfer of disease and were included in each T-cell–challenged group
of transplanted animals to prove the efﬁciency of the diabetic splenocytes.GENE COMBINATION TRANSFER TO ISLETS 209
have also shown by FACS analysis that 2 genes may colocal-
ize in the same islet cell and that the majority of infected cells
express both transgenes. This expression does not appear to in-
terfere with graft function in vivo. The blood glucose levels of
diabetic animals normalize at comparable rates whether given
modiﬁed or control islet grafts (Figure 4).
Ourinvivodatashowthattransplantedisletsoverexpressing
IRAP alone functioned longer than MnSOD and IDO and sig-
niﬁcantly longer than controls after exposure to diabetogenic
T-cells. Therefore, we included it in the combination trials to
determine if there was any indication of a positive synergistic
effect. Our reasons for coupling IRAP with IDO were based in
part on observations from previous studies such as those from
Munn and colleagues [6], who put forth the idea that IDO ex-
pression in the environment of antigen-presenting cells may be
able not only to inhibit T-cell proliferation, but also to induce
T-celldeath.TheyfoundthatT-cellsactivatedundertryptophan-
deﬁcient conditions arrest midway through the G1 stage of the
cellcycleandbecomesusceptibletoapoptosis.ArrestingT-cell
activationatthemid-G1stageisalsothewaysomeimmunosup-
pressivedrugswork,includingrapamycinandleﬂunomide[21,
22]. Therefore, combining IDO with IRAP could then provide
an additional dimension to islet protection by blocking both
T-cell activation and IL-1β receptor binding on the target cell.
Other recent studies have revealed that although MnSOD
is a potent antioxidant enzyme, its activity is thought to be
defeated over time because of increased NO levels. This is
believed because the reaction of O2
− combining with NO to
produce peroxynitrite (OONO−)i sf aster than the O2
− dismu-
tationreactionofMnSOD[23].Theresultantcytotoxicradical,
peroxynitrite, accumulates to a concentration that effectively
quenches MnSOD activity, thereby allowing oxygen radicals
to damage tissue. IRAP expression works to prevent NO from
beinggeneratedinresponsetoincreasedIL-1β levels[24].With
less NO to form peroxynitrite, the length of time MnSOD is ac-
tive should increase and therefore the length of time the islets
function in grafts overexpressing MnSOD and IRAP should
also increase beyond those overexpressing MnSOD alone.
Themodelusedinourstudytestsatherapeuticgene’sability
to protect islets against the destructive power of a full-blown
autoimmune attack. The results show that these gene combina-
tions could at most protect the islet grafts for the same length
of time as could the individual genes. The mean length of graft
function for islets bearing the combinations of IDO and IRAP
(41 ± 20 days), MnSOD and IRAP (50 ± 18 days), or MnSOD
and IDO (41 ± 22) was not statistically different compared
to the length of graft function of IDO alone (43 ± 15 days),
MnSOD alone (47 ± 14), or IRAP alone (46 ± 23).
There are several possible explanations for our results. The
lack of synergistic action of these genes could be due to differ-
ent subpopulations of autoreactive T-cells acting through dif-
ferent pathways. Each subset can only be blocked for a certain
amount of time before the obstacle is overcome. The combina-
tion of genes examined here seems not to enhance the blockade
of all T-cell subpopulations. Instead, they offer a limited block-
ing, each directed to a speciﬁc T-cell–mediated mechanism.
Another explanation is that autoreactive T-cells quickly learn
how to adapt their receptors and biochemical activities so as
to be only temporarily limited by the immunomodulatory ge-
netic expression transferred into the target islets. Additionally,
the protected factors generated by the transgenic proteins may
be produced/released in decreasing amounts with time, even-
tually allowing the T-cells to supercede. One last possibility is
that because there was less protein detected in the supernatant
of the IRAP grafts after 90 days (Table 2), some of the Ad-
IRAP–infected islet cells either stopped secreting the protein
or died/were killed and therefore IRAP production was lost.
The reasons we had for choosing these antioxidant and im-
munoregulatory genes were sound. Previous in vitro testing
proved that these genes were present in the target cells after
adenoviral infection and both the islet cells and the genes func-
tioned normally and as expected. The gene proteins were pro-
duced by the target cells and detected in the medium super-
natant. Nevertheless, the dynamics of a functioning complex
immunesysteminvivoisstillnotentirelyunderstood.Wewere
able to signiﬁcantly prolong islet function with overexpression
of IRAP, IDO, and MnSOD gene proteins but a combination
of these genes did not work in synergy to extend graft function
further than any gene individually.
In conclusion, even though these speciﬁc genes did not pro-
vide complete protection to donor islets, the method of manip-
ulating islets ex vivo with therapeutic genes has proven to be
of value in extending the functional life of transplanted islets
in this mouse model of autoimmune diabetes. It is an excellent
system to test other candidate genes to determine in vivo thera-
peutic ability and does not preclude being used in conjunction
with other therapies aimed at curing this complex disease.
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